Raymond James Starts Coverage on Phathom Pharmaceuticals With Strong Buy

Raymond James initiates coverage on Phathom Pharmaceuticals with a Strong Buy rating and a $28 price target, highlighting Voquezna’s unique FDA-approved profile and strong long-term outlook.